Technical Analysis for INO - Inovio Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 3.31 -0.90% -0.03
INO closed down 0.9 percent on Monday, May 20, 2019, on 60 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical INO trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
NR7 Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%

Older signals for INO ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company's DNA-based SynCon technology enables the design of vaccines capable of providing cross-protection against new, unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company's clinical programs include human papillomavirus/cervical cancer (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus, hepatitis B virus, human immunodeficiency virus, and malaria vaccines. It is also advancing preclinical research for a seasonal/pandemic influenza vaccine, as well as other products. Inovio Pharmaceuticals, Inc. has collaboration and license agreements with VGX International, Merck, and ChronTech. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1983 and is headquartered in Blue Bell, Pennsylvania.
Medicine Medical Specialties Infectious Diseases Cancers Prostate Cancer Influenza Vaccination Leukemia Vaccines Virus Influenza Vaccine Malaria Virology Seasonal/Pandemic Influenza Universal Flu Vaccine
Is INO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.3
52 Week Low 3.02
Average Volume 1,079,886
200-Day Moving Average 4.534
50-Day Moving Average 3.7372
20-Day Moving Average 3.707
10-Day Moving Average 3.588
Average True Range 0.1662
ADX 18.29
+DI 11.3643
-DI 26.5855
Chandelier Exit (Long, 3 ATRs ) 3.4814
Chandelier Exit (Short, 3 ATRs ) 3.7486
Upper Bollinger Band 4.0911
Lower Bollinger Band 3.3229
Percent B (%b) -0.02
BandWidth 20.722957
MACD Line -0.1154
MACD Signal Line -0.0608
MACD Histogram -0.0545
Fundamentals Value
Market Cap 298.65 Million
Num Shares 90.2 Million
EPS -1.07
Price-to-Earnings (P/E) Ratio -3.09
Price-to-Sales 9.78
Price-to-Book 3.53
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.48
Resistance 3 (R3) 3.47 3.42 3.45
Resistance 2 (R2) 3.42 3.37 3.42 3.44
Resistance 1 (R1) 3.36 3.35 3.39 3.37 3.43
Pivot Point 3.31 3.31 3.32 3.31 3.31
Support 1 (S1) 3.25 3.26 3.28 3.26 3.19
Support 2 (S2) 3.20 3.24 3.20 3.18
Support 3 (S3) 3.14 3.20 3.17
Support 4 (S4) 3.15